Europe Neoantigens Market
The European neoantigens market is divided into Germany, the UK, France, Italy, and Spain. The region holds a significant market share in the global neoantigens market. The market growth is attributed due to the increasing research & development in the bioinformatics field across the countries. Also, the rising incidence of cancer is likely to raise the demand for neoantigens targeted. Germany is much ahead in terms of the healthcare industry. It has the presence of market leaders from across the world. Also, there are well-established players across the country that is contributing to the overall healthcare industry. The number of cancer cases in Germany have increased due to risk factors like smoking, unhealthy diet, or infection. As per the Globocan 2020, the total number of cancer cases was 628,519 in 2020, of which 344,451 were in males and 284,068 female cases. The top five cancer types in Germany are breast, lung, prostate, colon, bladder, and other cancer. Furthermore, increasing prevalence of cancer has led to the development of increased number of studies on cancer in Germany which is likely to favor market growth. For instance, In November 2019, NEC Corporation and VAXIMM AG, a privately held, Swiss-German biotech company that is dedicated in developing vaccines for patients suffering from cancer collaborated to develop novel personalized neoantigen cancer vaccines. Similarly, in 2017, a proof-of-principle studies by a team in Europe demonstrated that neoantigen vaccines can direct immune responses against cancer cells in patients with recurrent melanoma. In the European study, researchers in Germany and Austria created a vaccine containing a mix of 10 RNA molecules encoding neoantigen peptides, which boosted immune activity against tumours in 9 out of 13 patients in the study. Thus, increased offering for neoantigens is likely to influence the market's growth in the forecasted period.
In Europe, there is an exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. As per the Worldometer, as of May 6th, 2020, Spain, the UK, Italy, Germany, and France recorded 3,551,262; 4,425,940; 4,070,400; 3,469,448; and 5,706,378, COVID-19 cases, respectively, and the deaths toll is also high in these countries. As per the news article, due to COVID-19 emergency, access to chemotherapy, scans, transplants, and surgery has become difficult for thousands of cancer patients in Italy. According to the research led by Codice Viola, charity that supports pancreatic cancer patients found that more than 500 breast or pancreatic patients’ appointments for chemotherapy or radiotherapy were postponed. Additionally, 64% of surgical procedures were postponed and more than half of the follow-up appointments rescheduled. Additionally, in Europe, many of the cancer vaccine development companies have been directed to develop COVID-19 vaccine. For instance, on April 2020, NEC announced that, after its neoantigen cancer vaccine project, it is planning to develop COVID-19 vaccine using AI with a close collaboration with NOI, a biotechnology subsidiary located in Oslo, Norway. Also, patient enrollment in clinical trials has been significantly declined. These factors are likely to have negative impact on the market growth.
Strategic insights for the Europe Neoantigens provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 86,165.00 thousand |
| Market Size by 2028 | US$ 341,855.35 thousand |
| Global CAGR (2023 - 2028) | 31.7% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Treatment
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe Neoantigens refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The neoantigens market in Europe is expected to grow from US$ 86,165.00 thousand in 2023 to US$ 341,855.35 thousand by 2028; it is estimated to grow at a CAGR of 31.7% from 2023 to 2028. Use of AI in neoantigen vaccine development; private organizations and companies as well as government associations are equally participating in the development of immunotherapy methods by integrating IT with life sciences. Healthcare IT and neoantigen market players are integrating artificial intelligence (AI) technology with neoantigens to identify patient-specific immunogenic cancer mutations. In May 2020, NEC Corporation, an IT and network technologies company, and Transgene, a company involved in the development of virus-based immunotherapies for cancer treatment, announced to publish their findings in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2020 (AACR Virtual Annual Meeting II) in June 2020. The companies were looking forward to announcing data related to a prediction algorithm that can be used to customize an individualized therapeutic vaccine TG4050 for patients as per their immunogenic cancer mutation is accurate in June 2020 at AACR Virtual Annual Meeting II. The customization of TG4050 would be more specific, and it would be possible for a large set of candidate mutations. The TG4050 was designed by using the myvac technology of Transgene and Neoantigen Prediction System of NEC. The prediction system is an advanced AI technology that has been in use in the field of oncology. The TG4050 is developed to treat solid tumors and is currently in the Phase 1 clinical trial in the US and Europe. Thus, the integration of AI with neoantigen vaccine research is emerging as a key trend in the neoantigen market. This is bolstering the growth of the neoantigens market.
Based on treatment, the market is segmented into combination therapy, and mono therapy. In 2023, the combination therapy segment is estimated to have the largest share of the market. Based on
A few major primary and secondary sources referred to for preparing this report on the neoantigens market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Achilles Therapeutics plc, Frame Cancer Therapeutics, Genocea, Immunicum AB, Medigene AG, and Moderna, Inc among others.
The Europe Neoantigens Market is valued at US$ 86,165.00 thousand in 2023, it is projected to reach US$ 341,855.35 thousand by 2028.
As per our report Europe Neoantigens Market, the market size is valued at US$ 86,165.00 thousand in 2023, projecting it to reach US$ 341,855.35 thousand by 2028. This translates to a CAGR of approximately 31.7% during the forecast period.
The Europe Neoantigens Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Neoantigens Market report:
The Europe Neoantigens Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Neoantigens Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Neoantigens Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Neoantigens Market
